OBJECTIVE: This study investigated the potential use of serum follistatin (FST) as a marker for ovarian cancer alongside serum cancer antigen-125 (CA-125). METHODS: Serum samples were collected from patients with ovarian cancer (n = 45), benign ovarian cysts (n = 40) or other cancers (n = 100) and from healthy subjects (n = 60) for the determination of FST and CA-125 levels using enzyme-linked immunosorbent assays. Expression of FST in ovarian tissue was investigated using immunohistochemical staining. RESULTS: Compared with healthy subjects and patients with benign ovarian cysts, serum FST and CA-125 levels were significantly increased in patients with ovarian cancer. Using the 95% confidence interval for the healthy subjects group as the cut-off value, tumour marker sensitivity and specificity in ovarian cancer were 53.3% and 97% for FST and 77.8% and 84% for CA-125, respectively. Tissue expression of FST protein was more pronounced in ovarian cancer than in normal ovary. CONCLUSIONS: The serum FST level was elevated in the peripheral blood of patients with ovarian cancer and has potential as a tumour marker for ovarian cancer diagnosis. It may be particularly useful when combined with CA-125 detection to reduce the number of false-positive results.
Introduction
Ovarian cancer is the most common cause of death from gynaecological tumours. 1 Cancer antigen-125 (CA-125) is frequently used as a tumour marker in the diagnosis of ovarian cancer; however, it has been shown that simultaneous screening with CA-125 and transvaginal ultrasound does not reduce mortality from ovarian cancer compared with usual care. 2 Identification of more effective tumour markers that can be used alongside CA-125 for the diagnosis of ovarian cancer is, therefore, crucial.
Follistatin (FST), originally isolated from porcine and bovine follicular fluid, is a monomeric glycoprotein that inhibits release of follicle-stimulating hormone from the pituitary. 3, 4 It is a specific binding protein of activin and is involved in the regulation of multiple physiological and pathological functions, and has important roles in early embryonic development, differentiation of ovarian granulosa cells, liver fibrosis and polycystic ovarian syndrome. 5, 6 In addition Serum follistatin levels in patients with ovarian cancer to being expressed in gonadal tissue, immunoreactive FST protein has also been detected in peripheral blood, its levels varying with physiological and pathological conditions such as pregnancy and cancer. 7, 8 In order to clarify the relationship between FST and ovarian cancer, serum levels of FST were measured in the peripheral blood of healthy subjects and patients with ovarian cancer, benign ovarian cysts or other malignant tumours; for comparison, serum CA-125 levels were also measured in healthy subjects and patients with benign and malignant ovarian disease. In addition, FST expression in normal ovary and ovarian cancer tissues was investigated using immunohistochemical staining.
Patients and methods

STUDY PARTICIPANTS
Women with pathologically confirmed stage I -III ovarian cancer, 9 benign ovarian cysts (excluding endometriosis) or other cancers were recruited sequentially from the First Hospital of Jilin University and from the China-Japan Union Hospital of Jilin University, Changchun, China, between January 2008 and June 2011. Malignant and benign ovarian diseases were classified according to the International Federation of Gynecology and Obstetrics. 9 Patients with endometriosis were excluded from the present study because high serum FST levels have been reported in endometriosis. 10 Age-matched healthy women attending the medical examination centre of the China-Japan Union Hospital of Jilin University for routine examinations were recruited as controls.
Written informed consent was obtained from all the study participants. The study protocol was approved by the Institutional Review Board of Jilin University, Changchun, China.
SERUM SAMPLES
Venous blood samples were collected from all patients in the morning of the second day after admission. Venous blood samples were similarly collected from healthy controls in the morning on the day of their routine examination. Serum was obtained by centrifuging the blood samples at 1518 g for 10 min at 4°C and was then stored at −80°C until analysed.
MEASUREMENT OF SERUM FST
Serum FST was measured in patients with ovarian cancer, benign ovarian cysts or other cancers and in healthy subjects using an enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Absorbance was measured at 450 nm to quantify FST levels.
MEASUREMENT OF SERUM CA-125
Serum CA-125 was measured in patients with ovarian cancer or benign ovarian cysts and in healthy subjects using the Elecsys ® CA-125 immunoassay (Boehringer-Mannheim, Mannheim, Germany), according to the manufacturer's instructions. In brief, a 40 µl sample was incubated with biotinylated anti-CA-125 monoclonal antibody (OC125, mouse) labelled with 1 mg/ml ruthenium (ruthenylated second tracer antibody complex, anti-CA-125-Ab-Ru[bpy] 3
2+
; Roche Diagnostics, Mannheim, Germany) for 9 min, followed by an additional 9-min incubation with streptavidin-coated paramagnetic beads. The reaction mixture was then drawn into a measuring cell, where the magnetic beads were captured, ProCell buffer containing tripropylamine (300 mmol/l phosphate buffer, 180 mmol/l tripropylamine, ≤ 0.1% detergent, preservative; pH 6.8) was added, a voltage (1.5 V) was applied and the resulting Serum follistatin levels in patients with ovarian cancer electrochemiluminescence was measured using a photomultiplier. 11
IMMUNOHISTOCHEMISTRY SAMPLES
Samples of normal ovary and ovarian specimens from patients presenting with serous cystadenocarcinoma or endometrioid carcinoma, two common types of ovarian cancer, who were subsequently shown to have positive serum FST levels were obtained from the pathology departments of the First Hospital of Jilin University and the China-Japan Union Hospital of Jilin University for immunohistochemical staining.
IMMUNOHISTOCHEMICAL STAINING PROCEDURE
For immunohistochemical staining, 12 serial sections 3 µm in thickness were cut from paraffin-embedded blocks, placed in 0.01 mol/l citrate buffer (pH 6.0) and autoclaved at 121°C for 10 min for antigen retrieval, before being incubated with 3% hydrogen peroxide in methanol for 30 min at room temperature to block endogenous peroxidase. The sections were then washed three times with 0.02 mol/l phosphate buffered saline (PBS; pH 7.4) and blocked with 2% bovine serum albumin in PBS at room temperature for 30 min. Each section was incubated with mouse anti-FST monoclonal antibody (1 : 200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. FST protein expression was assayed using an Ultrasensitive Streptavidin/ Peroxidase kit (Beijing Zhongshan Biotechnology Co., Beijing, China). Briefly, sections were incubated with goat antimouse biotinylated secondary antibody against immunoglobulin G for 10 min at room temperature, followed by incubation with streptavidin-horseradish peroxidase for 10 min at room temperature. Immunoreaction products were visualized using 0.05% diaminobenzidine and 0.03% hydrogen peroxide and counterstained with haematoxylin. After being dehydrated, cleared and mounted, the sections were viewed and photographed using an Olympus BX51 microscope and DP71 camera (Olympus, Tokyo, Japan).
Sections of endometrioid carcinoma incubated with normal mouse immunoglobulin G instead of anti-FST antibody were used as negative controls.
STATISTICAL ANALYSES
Continuous variables were checked for normality using the one-sample Kolmogorov-Smirnov test and were expressed as mean ± SD. Results from different groups were compared using oneway analysis of variance and the Newman-Keuls multiple comparison post-hoc procedure. Using the 95% confidence interval for the group of healthy subjects as the cut-off value, the sensitivity and specificity of FST and CA-125 as markers for ovarian cancer were calculated and a receiver operator characteristic (ROC) curve was constructed to investigate their diagnostic efficacies. A P-value ≤ 0.05 was considered to be statistically significant. Data analyses were performed using IBM ® SPSS ® statistical software version 19.0 (IBM, New York, NY, USA).
Results
STUDY PARTICIPANTS
The study participants comprised 60 healthy women, 45 patients with stage I -III ovarian cancer, 40 patients with benign ovarian cysts, and a total of 100 patients with other cancers, comprising 20 with hepatoma, 20 with gastric adenocarcinoma, 20 with renal cell carcinoma, 20 with osteosarcoma and 20 with breast cancer. Serum follistatin levels in patients with ovarian cancer Of those patients with ovarian cancer, 17 had serous cystadenocarcinoma, 11 had mucinous cystadenocarcinoma, eight had endometrioid carcinoma, six had clear cell carcinoma and three had squamous cell carcinoma. Of those with benign ovarian cysts, 19 patients had serous cystadenoma, 11 had mucinous cystadenoma and 10 had other benign ovarian cysts. Demographic and clinical characteristics of the study participants are given in Table 1 . There were no statistically significant differences in age between any of the groups (Table 1 ).
SERUM FST AND CA-125 LEVELS
Levels of serum FST in patients with ovarian cancer were significantly higher than those in healthy subjects and patients with benign ovarian cysts (P < 0.01 for both; Fig. 1A ).
There was no significant difference between serum FST levels in patients with benign ovarian cysts and those in healthy subjects.
Levels of serum CA-125 in patients with ovarian cancer were also significantly higher than those in healthy subjects and patients with benign ovarian cysts (P < 0.01 for both Fig. 1B ). In addition, CA-125 levels were significantly higher in patients with benign ovarian cysts than in healthy subjects (P < 0.01).
Serum FST levels in patients with hepatoma (P < 0.01), osteosarcoma (P < 0.05) and breast cancer (P < 0.05) were significantly increased compared with healthy subjects (Fig. 1C) . Levels of serum FST in patients with gastric adenocarcinoma or renal cell carcinoma, however, were not significantly different from those in healthy subjects.
Using the 95% confidence interval for the healthy subjects group as the cut-off value (FST ≥ 2.1 µg/l), serum FST levels were positive in 24 (53.3%) patients with ovarian cancer, two (5.0%) patients with benign ovarian cysts and one (1.7%) healthy subject ( Table 2) , giving an overall sensitivity and specificity for FST for the detection of ovarian cancer of 53.3% and 97%, respectively.
Again using the 95% confidence interval for the healthy subjects group as the cut-off value (CA-125 ≥ 38.4 IU/l), serum CA-125 levels were positive in 35 (77.8%) patients with ovarian cancer, 10 (25.0%) patients with benign ovarian cysts and six (10.0%) healthy subjects (Table 2) , giving an overall sensitivity and specificity for CA-125 for the detection of ovarian cancer of 77.8% and No statistically significant differences in age between any of the groups (P > 0.05). Serum follistatin levels in patients with ovarian cancer 84%, respectively. Positive FST levels with other cancers were seen in five (25.0%) patients with hepatoma, four (20.0%) with breast cancer, four (20.0%) with osteosarcoma, two (10.0%) with gastric adenocarcinoma, and one (5.0%) with renal cell carcinoma ( Table 2 ).
CORRELATION OF POSITIVE FST AND CA-125 LEVELS
Of the 24 ovarian cancer patients who were positive for serum FST, 23 (95.8%) were also positive for serum CA-125 ( Fig. 2A) , suggesting there is a close correlation between FST and CA-125 levels in ovarian cancer diagnosis. In addition, all 16 patients with a false-positive result for serum CA-125 (six healthy subjects and 10 with benign ovarian cysts) were negative for serum FST (Fig. 2B) .
When the sensitivity and specificity of FST and CA-125 were plotted on a ROC curve (Fig. 2C) , the area under the curve was 0.902 for FST and 0.886 for CA-125, indicating that these two markers have similar accuracy in discriminating women with ovarian cancer from healthy controls.
EXPRESSION OF FST PROTEIN IN OVARIAN TISSUE
To investigate the reason for high serum FST levels in ovarian cancer patients, FST protein expression was examined in specimens of ovarian serous cystadenocarcinoma (n = 8) and endometrioid carcinoma (n = 5) from patients who were positive for serum FST and in normal ovarian tissue (n = 3). FST immunoreactivity was detectable in serous cystadenocarcinoma and endometrioid carcinoma tissue in patients with positive serum FST levels and in normal ovarian tissue, but was more pronounced in ovarian cancer tissue (Fig. 3 ).
Discussion
Ovarian cancer is one of the most common cancers in females. 1 It has been termed a 'silent killer', since many ovarian cancers are asymptomatic in the early stages and so do not present until the disease is at an advanced stage. Most women with ovarian cancer are, therefore, diagnosed with advanced stage disease, which has a 5-year survival rate of only 30%. 13 In a study on the effect of screening with CA-125 and transvaginal ultrasound on ovarian cancer mortality at 10 screening centres across the USA between November 1993 and July 2001, there were 118 deaths caused by ovarian cancer (3.1 per 10 000 person-years) in the intervention group and 100 deaths (2.6 per 10 000 person-years) in the usual care group, suggesting that screening with CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality. 2 Buys et al. 2 also reported that serum CA-125 had a high false-positive diagnostic rate in benign ovarian tumours, which is consistent with the results of the present study. Early diagnosis is important for improving the survival and quality of life for patients with The 95% confidence interval for the healthy subjects was used as the cut-off value for each marker: FST ≥ 2.1 µg/l; CA-125 ≥ 38.4 IU/l. Serum follistatin levels in patients with ovarian cancer ovarian cancer; the need to find an effective early diagnostic marker for ovarian cancer is still very urgent. 14 The protein FST is involved in the regulation of ovulation and cell proliferation and the repair of epithelial damage in the ovary. 15 -18 FST and activin are generally expressed together, and over-or underexpression of either will induce an imbalance in the activin-FST system, which has been shown to be associated with a number of ovarian disorders and pathological processes, including cancer genesis. 19 -23 In the present study, increased serum FST levels were found in patients with various malignant tumours, but occurred most frequently in patients with ovarian cancer, and gave a sensitivity of 53.3% for the detection of ovarian cancer.
On immunohistochemical staining, FST protein expression was more pronounced in ovarian cancer tissues than in normal ovarian tissue, suggesting that the increased levels of FST in the peripheral blood of patients with ovarian cancer may be directly released from ovarian cancer cells. High serum FST levels have been reported in endometriosis; 10 therefore, patients with endometriosis were excluded from the present study. Currently, the biomarker CA-125, which has been shown to be raised in ovarian cancer before the onset of clinical symptoms, 24 is widely used in clinical practice. CA-125 is expressed by fetal amniotic and coelomic epithelium, and by adult tissues derived from the coelomic (mesothelial cells of the pleura, pericardium and peritoneum) and mullerian (tubal, endometrial and endocervical) epithelia. 25 Despite the benefits associated with the use of CA-125 to detect reproductive system tumours, many challenges still exist. The primary one is the low sensitivity in detecting early-stage ovarian cancer and the high incidence of false-positive results, since levels of CA-125 are naturally increased with ovulation and may be elevated in endometriosis, fibroids and many other benign conditions. 26, 27 In the present study, the overall sensitivity of serum FST was lower (53.3%) than that of CA-125 (77.8%), however the false-positive rate of CA-125 was 25.0% in patients with benign ovarian cysts and 10.0% in healthy subjects, whereas the false-positive rate of FST was only 5.0% in patients with benign ovarian cysts and 1.7% in healthy subjects. Moreover, the specificity of serum FST was 97%, in contrast to CA-125 which had a specificity of 84%. These findings suggest that serum FST has potential as a tumour marker for ovarian cancer diagnosis and may be particularly useful when combined with CA-125 to reduce the number of falsepositive results.
In summary, the present study demonstrated that FST levels were elevated in the peripheral blood of patients with ovarian cancer. Along with CA-125, the detection of serum FST may be useful in the clinical diagnosis of ovarian cancer.
